ArticleJNCI cancer spectrum2021
Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Article in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02306096 (SCAN-B), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.Acta oncologica (Stockholm, Sweden) · 2024Trial
- ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner.Communications biology · 2026Article
- Cutting-edge advances in endocrine therapy for breast cancer (Review).Oncology letters · 2026Review
- Multi-cohort and single-cell profiling of aging genes reveals prognostic and therapeutic targets in breast cancer.iScience · 2026Article
- A Systematic Review of Evidence for the Cost of Therapeutic Resistance in Cancer.bioRxiv : the preprint server for biology · 2025Article
- ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer.Cancers · 2025Article
- Article
- EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology.NPJ breast cancer · 2024Article
- Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.Scientific reports · 2024Article
- Article
- Exosomal DNA: Role in Reflecting Tumor Genetic Heterogeneity, Diagnosis, and Disease Monitoring.Cancers · 2023Review
- Review
- Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.International journal of molecular sciences · 2023Article
- Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and ChildhoodHemaSphere · 2022Article
- Article
- RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer.NPJ breast cancer · 2022Article
- Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.Drug design, development and therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene Methods: We analyzed 3217 population-based invasive primary (nonmetastatic) breast cancers (within the SCAN-B study, ClinicalTrials.gov NCT02306096), sampled from initial diagnosis prior to any treatment, for the presence of Results: We identified Conclusions: These population-based results indicate that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.